A study of the antimicrobial activity of selected synthetic and naturally occurring quinolines

To cite this version:

HAL Id: hal-00556356
https://hal.archives-ouvertes.fr/hal-00556356
Submitted on 16 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Accepted Manuscript

Title: A study of the antimicrobial activity of selected synthetic and naturally occurring quinolines

Authors: F. O’Donnell, T.J.P. Smyth, V.N. Ramachandran, W.F. Smyth

PII: S0924-8579(09)00353-7
DOI: doi:10.1016/j.ijantimicag.2009.06.031
Reference: ANTAGE 3088

To appear in: International Journal of Antimicrobial Agents

Received date: 27-4-2009
Revised date: 17-6-2009
Accepted date: 23-6-2009

Please cite this article as: O’Donnell F, Smyth TJP, Ramachandran VN, Smyth WF, A study of the antimicrobial activity of selected synthetic and naturally occurring quinolines, International Journal of Antimicrobial Agents (2008), doi:10.1016/j.ijantimicag.2009.06.031

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
A study of the antimicrobial activity of selected synthetic and naturally occurring quinolines

F. O'Donnell, T.J.P. Smyth, V.N. Ramachandran, W.F. Smyth *

School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, Co. Derry, Northern Ireland BT52 1SA, UK

ARTICLE INFO
Article history:
Received 27 April 2009
Accepted 23 June 2009

Keywords:
Quinolines
Antimicrobial activity

* Corresponding author. Tel.: +44 28 70 32 44 25; fax: +44 28 70 32 49 65.
E-mail address: wf.smyth@ulster.ac.uk (W.F. Smyth).
ABSTRACT

The antimicrobial activities of 60 naturally occurring and synthetic quinolines were studied. The quinolines were organised into seven structural subgroups and, using an in-house microtitre assay, were tested against a range of Gram-positive and Gram-negative bacteria, including a hospital isolate of meticillin-resistant *Staphylococcus aureus* (MRSA). The quinolines exhibiting good bioactivity [i.e. low minimum inhibitory concentration (MIC)] against two *S. aureus* strains were then assessed for their antimicrobial activity against a range of eight clinically isolated MRSA strains. The study showed that 30 of the tested compounds displayed antimicrobial activity, mostly against Gram-positive bacteria. The effects of substituent groups on the bioactivity of these quinolines have also been discussed. The quinoline 4-hydroxy-3-iodo-quinol-2-one (11) exhibited significant antimicrobial activity, being active against the MRSA clinical isolates with MIC values comparable with the antibiotic vancomycin used in the treatment of MRSA infections. In particular, 4-hydroxy-3-iodo-quinol-2-one (11) showed MIC values of 0.097 µg/mL against an Irish hospital MRSA-1 strain and 0.049 µg/mL against a distinct MRSA strain as well as a non-typeable MRSA strain.
1. Introduction

The rise in antibiotic-resistant microorganisms in recent years has led to an increasing search for new antibiotics. Plant secondary metabolites have been used for centuries in traditional medicines and therefore represent a source of potentially active compounds [1]. Naturally occurring and synthetic quinoline derivatives have been studied for many years for their pharmacological activity, but only a few of these compounds have been developed for clinical use.

Mitscher et al. [2] found that the quaternary alkaloid pteleatinium chloride and the O-methylptelefolonium salt isolated from Ptelea trifoliata showed antimicrobial activity towards Staphylococcus aureus and Mycobacterium tuberculosis. A study by Fournet et al. [3] showed that the bioactivity of the plant Galipea longiflora against Leishmania amazonensis was due to 2-substituted quinoline alkaloids present in the plant, namely 2-propylquinoline and chimanine D.

Hanawa et al. [4] investigated the photo-activated antimicrobial activity of several furoquinoline derivatives such as skimmianine, kokusaginine, haplopine and flindersine against S. aureus. Towers et al. [5] carried out studies on the phototoxic effects of furoquinoline alkaloids. Five of the twelve compounds tested were active against Escherichia coli and Saccharomyces cerevisiae, namely isodictamnine, 7-desmethylskimmianine, maculosidine, maculine and dictamnine [5].
Skimmianine and kokusaginine have also shown good bioactivity against the fungus *Leucoagaricus gongylophorus* [6].

Use of quinoline antimalarials such as quinine, chloroquine and amodiaquine in the treatment of malaria is well known. Many other synthetic quinoline derivatives have pharmaceutical significance. One group of synthetic quinolines that has significant use as antimicrobials in the treatment of many infections is the quinolones [7]. Nalidixic acid was the first of this group of compounds to be introduced and was used for the treatment of urinary tract infections in the 1960s. In the 1980s a succession of quinolone antimicrobials were introduced that differed from nalidixic acid by having a fluorine substituent in the 6-position and a piperazinyl derivative in the 7-position. These compounds are often referred to as fluoroquinolones. They are broad-spectrum antimicrobials and are used to treat sexually transmitted diseases and infections of the urinary tract, gastrointestinal tract, respiratory tract, skin, and bones and joints [8].

This study reports the results of an investigation into the bioactivities of 60 quinoline derivatives against six different microorganisms by in-house microtitre assay. The minimum inhibitory concentration (MIC) of each quinoline derivative is reported. Quinolines that initially showed a low MIC against meticillin-resistant *S. aureus* (MRSA) and/or *S. aureus* were further tested against eight clinically isolated MRSA.
2. Materials and methods

2.1. Quinolines

The quinoline derivatives investigated were available either from previous isolation from plant sources or from previous synthetic studies carried out in The University of Ulster, Coleraine, Northern Ireland [9–11]. Edulitine (7), lunacridine (24), veprisine (29), vepridimerine A (37), platydesmine (39), balfouridine (41), lemobiline (42), dictamnine (44), γ-fagarine (45), skimmianine (46), evoxine (49), choisyine (50) and ribalinine (60) were all obtained from plant sources. The remainder of the quinolines were prepared synthetically in the laboratory, for example the synthesis of pyrano(3,2-c)quinol-5-one alkaloids [12]. Some of the quinoline derivatives were intermediates in the synthesis of naturally occurring quinolines. The names of the quinolines used are given in Tables 1–4 and their corresponding structures are illustrated in Figures 1–7. All samples were dissolved in acetone and prepared at a concentration of 6.67 mg/mL.

2.2. Microtitre assay

The MIC values of the quinoline derivatives were estimated according to a previously reported microtitre method [13]. Lane 1 contained a blank, i.e. 100 μL of Mueller–Hinton broth (MHB). Lane 2 comprised of the positive control (acetone), containing the initial concentration of acetone (15 μL) along the lane with 10 μL of sterile water and 25 μL of sterile MHB. The negative control was in lane 3, with each well containing 25 μL of sterile water and 25 μL of the antibiotic added to Well 1 of the lane followed by
serial double dilutions down to Well 12 of the lane. The final concentration range for oxacillin started at 21.6 \( \mu \text{g/mL} \) at Well 1 followed by serial dilution to 0.0105 \( \mu \text{g/mL} \) at Well 12. The concentration of vancomycin and trimethoprim antibiotics started at 25 \( \mu \text{g/mL} \) for Well 1 down to 0.0122 \( \mu \text{g/mL} \) at Well 12. Lanes 4–8 contained the pure quinolines to be tested for antibacterial activity, which were made up in acetone from a stock solution of 6.67 mg/mL. To each well of these lanes, 25 \( \mu \text{L} \) of sterile water was added, apart from the first two wells. In Well 1, 20 \( \mu \text{L} \) of sterile water was added followed by 30 \( \mu \text{L} \) of the test compound (final starting concentration in Well 1 was 1000 \( \mu \text{g/mL} \)), which was then serially diluted down every second well to Well 11 of each lane. In Well 2, 30 \( \mu \text{L} \) of sterile water was added followed by 20 \( \mu \text{L} \) of the test compound (final starting concentration in Well 2 was 666 \( \mu \text{g/mL} \)), which was serially diluted every second well down to Well 12. In this way, two concentration ranges were on the one plate with a starting concentration in Well 1 of 1000 \( \mu \text{g/mL} \) and a final concentration of 20.8 \( \mu \text{g/mL} \) in Well 12. The highly active compound 4-hydroxy-3-iodo-quinol-2-one (11) required a different concentration range starting at 100 \( \mu \text{g/mL} \) in Well 1 followed by double dilution down each well to a final concentration of 0.049 \( \mu \text{g/mL} \) in Well 12. All the microorganisms, which were grown overnight in MHB, were adjusted to \( 10^6 \) cells/mL before use, according to their optical density at 650 nm in MHB. Apart from Lane 1, all the wells of the microtitre plate were inoculated with 50 \( \mu \text{L} \) of bacterial suspension and were sealed with Parafilm\textsuperscript{TM} and incubated at 37 °C for 24 h in a Stuart orbital incubator (SI 50; Rhys International Ltd.,
Bolton, UK) at 50 rpm. Iodonitrotetrazolium chloride (INT) has been shown to the best indicator for determining microbial growth, producing a stable pink colour when there is microbial activity [14]. Following addition of INT (Sigma-Aldrich Co. Ltd., Poole, UK) and incubation, the MIC was determined as the lowest sample concentration at which no pink colour appeared. For each compound, the assay was performed in triplicate to ensure reproducible results.

2.3. Bacteria and antibiotics

The antimicrobial activities of the compounds were tested against the following bacteria: *Bacillus subtilis* ATCC 6051; *Micrococcus luteus* (University of Ulster, Coleraine, culture collection); *S. aureus* ATCC 12600; MRSA clinical isolate (Coleraine hospital); and the Gram-negative bacteria *E. coli* ATCC 11775 and *Salmonella enterica* serovar Typhimurium ATCC 14028. Quinolines that were particularly active against MRSA and/or *S. aureus* were further tested against eight hospital strains of MRSA: epidemic MRSA-15 (EMRSA-15); epidemic MRSA-16 (EMRSA-16); Irish hospital MRSA-1 (IMRSA-1); Irish hospital MRSA-2 (IMRSA-2); a non-typeable MRSA strain (NTMRSA); a distinct MRSA strain (DMRSA); community-acquired Hodgkin MRSA (HMRSA); and community-acquired Charles–Worth MRSA (CWMRSA). Vancomycin was used as the antibiotic control against these clinical MRSA isolates.

The antibiotics oxacillin, vancomycin and trimethoprim were obtained from Sigma-Aldrich (Poole, UK). Stock solutions of 0.173 mg/mL oxacillin and
0.2 mg/mL vancomycin and trimethoprim were prepared. The indicator \( p \)-INT was purchased from Sigma-Aldrich.

3. Results and discussion

The results are discussed under the different structural subgroups, comprising the quinol-2-ones, 3-C-dimethylallylquinol-2-ones, flindersine derivatives, quinoline dimers, dihydrofuroquinolines, linear and angular furoquinolines, and other quinolines. In this study, no bioactivity was defined as an MIC >1000 \( \mu \text{g/mL} \), mild bioactivity as an MIC in the range 501–1000 \( \mu \text{g/mL} \), moderate bioactivity as an MIC in the range 126–500 \( \mu \text{g/mL} \), good bioactivity as an MIC in the range 26–125 \( \mu \text{g/mL} \), strong bioactivity as an MIC in the range 10–25 \( \mu \text{g/mL} \) and very strong bioactivity as an MIC <10 \( \mu \text{g/mL} \).

3.1. Quinol-2-ones

The MICs of the 16 quinol-2-ones and the antibiotic controls are given in Table 1 and the structures of the quinol-2-ones are shown in Fig. 1. 4-Hydroxy-1-methyl-quinol-2-one (1) and 4-methoxy-1-methyl-quinol-2-one (2) were found to be inactive against the six microorganisms. However, 1,3-dimethyl-4-hydroxy-quinol-2-one (3), with an extra methyl group compared with (1), showed mild bioactivity (MIC = 1000 \( \mu \text{g/mL} \)) against MRSA, \textit{B. subtilis} and \textit{E. coli} and moderate activity (MIC = 500 \( \mu \text{g/mL} \)) against \textit{S. aureus} and \textit{M. luteus}. The presence of the extra methyl group in the 3-position of (3) in comparison with (1) may contribute to its activity.
among this group of compounds. 7,8-Dimethoxy-4-hydroxy-quinol-2-one (5) had moderate activity against the Gram-negative microorganism *E. coli* with an MIC of 500 µg/mL but was not active against the other microorganisms. When a methoxyl group was not present at the 7-position, as for 8-methoxy-4-hydroxy-quinol-2-one (6), the compound was no longer active against *E. coli* but showed mild activity against MRSA, *S. aureus* and *M. luteus*. When the 4-hydroxy group in (6) was replaced with a methoxyl group or an ethoxyl group, there was no activity against the microorganisms, as seen with edulitine (7) and 4-ethyloxy-8-methoxy-quinol-2-one (8). It can be tentatively suggested that a 4-hydroxy substituent may contribute towards bioactivity.

4-Hydroxy-3-iodo-7,8-dimethoxy-quinol-2-one (9) had an MIC of 250 µg/mL against MRSA and *M. luteus* and an MIC of 166.5 µg/mL against *S. aureus*. 4,7,8-Trimethoxy-3-iodo-quinol-2-one (10) was more active than (9) against *S. aureus* (MIC = 125 µg/mL), *M. luteus* (MIC = 125 µg/mL) and *E. coli* (1000 µg/mL) but was less active against MRSA (MIC = 500 µg/mL). 4-Hydroxy-3-iodo-quinol-2-one (11) had very strong activity against all six microorganisms, with an MIC of 0.39 µg/mL against MRSA, *M. luteus* and *B. subtilis*, an MIC of 0.195 µg/mL against *E. coli* and *S. Typhimurium* and an MIC of 6.25 µg/mL against *S. aureus*. Regarding these three compounds, it appears that iodine at position 3 and the absence of substitution in the benzene ring significantly enhances the bioactivity of these quinol-2-ones.
4-Geranyloxy-quinol-2-one (13) had an MIC of 250 \( \mu g/mL \) against MRSA and \textit{S. aureus} and an MIC of 1000 \( \mu g/mL \) against \textit{M. luteus}. Quinol-2-ones with relatively long side chains in the 3-position, i.e. compounds (14), (15) and (16), did not show bioactivity.

3.2. 3-C-dimethylallylquinol-2-ones

The MICs of the 3-C-dimethylallylquinol-2-ones are given in Table 2 and the structures of the compounds in this group can be seen in Fig. 2. The compounds in this group did not show activity against \textit{S. Typhimurium} and only one compound (26) showed mild activity against \textit{E. coli} and \textit{B. subtilis}. 4-Hydroxy-3-(3’-methylbut-2’-enyl)-quinol-2-one (17) showed mild activity against \textit{M. luteus} but was not active against any of the other microorganisms. 4-Hydroxy-6-methoxy-3-(3’-methylbut-2’-enyl)-quinol-2-one (18) differs from 4,6-dimethoxy-3-(3’-methylbut-2’-enyl)-quinol-2-one (19) by having a hydroxy group in the 4-position instead of a methoxyl group. They both showed very mild activity against MRSA and \textit{M. luteus} (MIC = 1000 \( \mu g/mL \)), but (18) was active against \textit{S. aureus} (MIC = 500 \( \mu g/mL \)). This suggests that the 4-hydroxy group may play a part in the bioactivity of (18) against \textit{S. aureus}. It was tentatively suggested in the last section that a 4-hydroxy substituent for quinol-2-ones may contribute towards their bioactivity. When an \textit{N}-methyl group is present in this group of compounds, as for compound (20), bioactivity is lost.
4-Hydroxy-8-methoxy-3-(3’-methyl-2’-hydroxybutyl)-1-methyl-quinol-2-one (22) had MICs of 500 µg/mL against MRSA and 250 µg/mL against S. aureus and M. luteus. This is an increase in bioactivity compared with 4-hydroxy-8-methoxy-3-(3’-methylbut-2’-enyl)-1-methyl-quinol-2-one (23), which has only mild activity against M. luteus (MIC = 1000 µg/mL), suggesting that the double bond in the pentyl side chain may minimise the compound’s activity. Lunacridine (24), with methylation of the 4-hydroxy group compared with (22), showed a decrease in activity and was only mildly active against S. aureus (MIC = 1000 µg/mL). This again supports the 4-hydroxy group enhancing bioactivity, as with compound (18). 4-Hydroxy-7,8-methylenedioxy-3-(3’methylbut-2’-enyl)-quinol-2-one (26) had an MIC of 1000 µg/mL against MRSA, E. coli and B. subtilis, an MIC of 500 µg/mL against S. aureus and an MIC of 333 µg/mL against M. luteus. Compound (26) was more bioactive than (17), possibly due to the presence of the 7,8-methylenedioxy group.

3.3. Flindersine derivatives

The MICs of the flindersine derivatives are given in Table 3 and the structures of these compounds can be seen in Fig. 3. The compounds in this group did not show any activity against B. subtilis or the Gram-negative microorganisms S. Typhimurium and E. coli. Veprisine (29) showed good bioactivity against S. aureus (MIC = 125 µg/mL) but had no activity against the other microorganisms. Veprisine (29) differs from 7,8-dimethoxyflindersine (28) only by having an N-methyl group. Flindersine
(27) had no activity at all, whereas N-methylflindersine (30) showed good activity against MRSA, S. aureus and M. luteus (MICs = 125 μg/mL). This suggests that the presence of the N-methyl group for this group of compounds may contribute to the activity of (29) and (30). 7-Hydroxyflindersine (31) showed good activity against MRSA, S. aureus and M. luteus, with an MIC of 125 μg/mL against all three microorganisms, which is identical to the bioactivity shown by (30). This suggests that the presence of an N-methyl group or a hydroxy group in the 7-position may increase the bioactivity of the basic flindersine molecule. However, when both groups are present in the same compound, as with 7-hydroxy-1-methylflindersine (32), the bioactivity is marginally decreased.

The presence of side chains may increase the bioactivity of the basic flindersine molecule as with 7-tetrahydropyranyloxyflindersine (33) and 7-dimethylallyloxy-N-methylflindersine (34). Compound (33) showed moderate activity against MRSA and M. luteus and good activity against S. aureus, with MIC values of 250 μg/mL and 125 μg/mL respectively. Compound (34) showed mild activity against MRSA (MIC = 1000 μg/mL) and moderate activity against S. aureus (MIC = 500 μg/mL) and M. luteus (MIC = 250 μg/mL).

3.4. Quinoline dimers

Compounds in this group (Fig. 4) showed no bioactivity against any of the microorganisms (Table 3).
3.5. Dihydrofuroquinolines

The five dihydrofuroquinolines (Fig. 5) tested showed no bioactivity (Table 3).

3.6. Linear and angular furoquinolines

Ten linear and angular furoquinolines were investigated. Their MICs are given in Table 4 and their structures are presented in Fig. 6. 5-Methylfuro-(3,2-c)-quinol-4-one (43) showed the greatest bioactivity against all six microorganisms. It had good activity against *M. luteus* (MIC = 125 μg/mL) and moderate activity against the other microorganisms, with MICs of 250 μg/mL for *S. aureus*, 333 μg/mL for MRSA and 500 μg/mL for *B. subtilis*, *E. coli* and *S. Typhimurium*. Compound (43) is the only one in this group that has an angular furan ring in the 3,2-c position, suggesting it may be significant in the compound’s bioactivity.

Dictamnine (44) is a direct biosynthetic precursor to γ-fagarine (45) and skimmianine (46). Dictamnine (44) was not active against any of the microorganisms, but γ-fagarine (45) showed moderate activity against MRSA, *S. aureus* and *M. luteus* (MICs = 500 μg/mL). γ-Fagarine (45) has a similar structure to dictamnine with an extra methoxyl group in the 8-position, suggesting that the presence of this methoxyl group could contribute to its activity. Skimmianine (46) has extra methoxyl groups in the 7- and 8-positions. However, (46) is only mildly active against *M.
luteus (MIC = 1000 µg/mL) and showed no activity against the other microorganisms. Thus, having a third methoxyl group in the 7-position appears to reduce the bioactivity of the molecule. 4-Methoxy-2-isopropyl-furoquinoline (47) showed moderate activity towards MRSA and S. aureus and mild activity towards M. luteus. This also suggests that the presence of the isopropyl side chain increases bioactivity compared with (44).

3.7. Other quinolines

The MICs of the compounds in this group are shown in Table 4 and their structures are given in Fig. 7. 2,4-Quinolinediol (53) showed mild activity against S. aureus (MIC = 1000 µg/mL). 2,4-Dichloroquinoline (54), 2,4-dimethoxyquinoline (55) and 2,4,8-trimethoxyquinoline (56) showed no activity against any of the microorganisms. This suggests that replacing the hydroxy groups with Cl or OCH$_3$ reduces the little bioactivity seen with (53). Orixine (57) showed moderate activity towards MRSA (MIC = 250 µg/mL). 5-Methoxy-2,2-dimethylidihydropyran-(2,3-b)-quinoline (58) showed moderate activity against MRSA (MIC = 500 µg/mL), S. aureus (MIC = 333 µg/mL) and M. luteus (MIC = 500 µg/mL) and mild activity against B. subtilis (MIC = 1000 µg/mL).

3.8. Bioactivity of selected quinolines against different strains of MRSA

Quinolines that showed an MIC of ≤125 µg/mL against MRSA and/or S. aureus were further tested against eight hospital isolates of MRSA. The results are shown in Table 5. The microtitre assay for some of the
compounds (10, 29, 30, 31 and 33) tested against IMRSA-1 is shown in Fig. 8.

As stated earlier, (10) was active against MRSA (MIC = 500 µg/mL) and S. aureus (MIC = 125 µg/mL). Compound (10) also showed good activity against the eight other strains of MRSA. It was most active against EMRSA-16 with an MIC of 62.5 µg/mL. It had an MIC of 125 µg/mL against EMRSA-15, IMRSA-1, IMRSA-2, NTMRSA, CWMRSA and HMRSA but was less active against DMRSA (MIC = 250 µg/mL). In the original testing, veprisine (29) was not active against MRSA but had good activity against S. aureus (MIC = 125 µg/mL). Therefore, (29) was tested further and it showed good to moderate activity towards all eight MRSA strains.

N-Methylflindersine (30) originally had an MIC value of 125 µg/mL against MRSA, S. aureus and M. luteus. It also has an MIC value of 125 µg/mL against all eight strains of MRSA. 7-Hydroxyflindersine (31) had an MIC of 125 µg/mL against IMRSA-1, DMRSA and CWMRSA, an MIC of 166.5 µg/mL against HMRSA, EMRSA-15 and EMRSA-16, and an MIC of 250 µg/mL against IMRSA-2 and NTMRSA. Compound (33) had an MIC of 250 µg/mL against IMRSA-1, IMRSA-2, DMRSA, CWMRSA, EMRSA-15 and EMRSA-16 but showed slightly more activity against NTMRSA and HMRSA (MIC = 166.5 µg/mL).
Compound (11) was noticeably the most active quinoline derivative against MRSA and all other microorganisms. It was most active against DMRSA and NTMRSA with MICs of 0.049 μg/mL. It had MICs of 0.097 μg/mL against IMRSA-1, 0.39 μg/mL against IMRSA-2 and EMRSA-15, 1.56 μg/mL against CWMRSA and HMRSA and 25 μg/mL against EMRSA-16. The MICs of the antibiotic vancomycin, commonly employed in the treatment of MRSA infections, are also given in Table 5. Compound (11) had an identical bioactivity to vancomycin against CWMRSA and HMRSA, whilst for the remaining MRSA strains, except EMRSA-16, it displayed a greater antimicrobial effect than vancomycin.

4. Conclusions

Sixty quinolines grouped in seven structural subdivisions were investigated for their bioactivities against a number of microorganisms. Thirty of the sixty quinolines showed bioactivity against the microorganisms investigated. The quinolines (26), (3), (10), (5), (43) and (11) showed activity against the Gram-negative bacterium *E. coli*. Unfortunately, the activity of these compounds against the two Gram-negative bacteria only ranged from mild to moderate, with the exception of (11) that had very strong bioactivity. The characteristic protective outer membrane of Gram-negative bacteria may play a role in the inactivity of many of the quinolines against them. In this study, many of the other quinolines demonstrated activity against one or more Gram-positive bacteria, with varying MIC values. The effects of the substituent groups on
the bioactivity of these quinolines have also been studied. Substituents
such as iodo, hydroxy, methyl and methoxy, in general, can enhance
bioactivity but this can depend on the number of substituents and their
relative position in the quinolone structure.

Of all the quinoline derivatives, 4-hydroxy-3-iodo-quinol-2-one (11)
showed very strong activity, with MICs of 0.195 μg/mL against S.
Typhimurium and E. coli, 0.39 μg/mL against MRSA, M. luteus and B.
subtilis and 6.25 μg/mL against S. aureus. When tested against eight
clinical MRSA strains, (11) also showed strong to very strong bioactivity.
Against the majority of clinical isolates the MICs for (11) were equal to or
lower than those for the antibiotic vancomycin used in the treatment of
MRSA infections. The MIC against both EMRSA-15 and IMRSA-2 was
0.39 μg/mL compared with 0.78 μg/mL for vancomycin. Very strong
activity was seen against IMRSA-1 (0.097 μg/mL), DMRSA and NTMRSA
(both MICs = 0.049 μg/mL) compared with vancomycin with MICs ranging
from 0.78 μg/mL to 1.56 μg/mL for the three hospital strains. Through
further investigation into the mode of action of these quinolines and the
testing of compounds of similar structure, in particular iodinated quinolines
such as (11), it is possible that new therapeutic compounds active against
MRSA could be discovered.

**Funding:** PhD funding.

**Competing interests:** None declared.
Ethical approval: Not required.
References


**Fig. 1.** Structures of the quinol-2-ones.

**Fig. 2.** Structures of the 3-C-dimethylallylquinol-2-ones.

**Fig. 3.** Structures of the flindersine derivatives.

**Fig. 4.** Structures of the quinoline dimers.

**Fig. 5.** Structures of the dihydrofuroquinolines.

**Fig. 6.** Structures of the linear and angular furoquinolines.

**Fig. 7.** Structures of the other quinoline derivatives.

**Fig. 8.** Microtitre assay for selected quinolines against Irish hospital MRSA-1 (IMRSA-1). Row 1 (R1) is the blank, R2 is the acetone control, R3 is the antibiotic vancomycin and R4–R8 are the quinolines (30), (31), (29), (33) and (10).
### Table 1

Minimum inhibitory concentrations (μg/mL) of quinol-2-ones and the antibiotic controls (oxacillin, vancomycin and trimethoprim)

<table>
<thead>
<tr>
<th>Quinol-2-one</th>
<th>MRSA</th>
<th>S. aureus</th>
<th>Micrococcus luteus</th>
<th>Bacillus subtilis</th>
<th>Escherichia coli</th>
<th>Salmonella Typhimurium</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-Hydroxy-1-methyl-quinol-2-one (1)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4-Methoxy-1-methyl-quinol-2-one (2)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>1,3-Dimethyl-4-hydroxy-quinol-2-one (3)</td>
<td>1000</td>
<td>500</td>
<td>500</td>
<td>1000</td>
<td>1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>7,8-Dimethoxy-1,3-dimethyl-4-hydroxy-quinol-2-one (4)</td>
<td>&gt;1000</td>
<td>1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>7,8-Dimethoxy-4-hydroxy-quinol-2-one (5)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>500</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>8-Methoxy-4-hydroxy-quinol-2-one (6)</td>
<td>1000</td>
<td>1000</td>
<td>1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Edulitine (7) [NS] a</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4-Ethylmethoxy-8-methoxy-quinol-2-one (8)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4-Hydroxy-3-iodo-7,8-dimethoxy-quinol-2-one (9)</td>
<td>250</td>
<td>166.5</td>
<td>250</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4,7,8-Trimethoxy-3-iodo-quinol-2-one (10)</td>
<td>500</td>
<td>125</td>
<td>125</td>
<td>&gt;1000</td>
<td>1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4-Hydroxy-3-iodo-quinol-2-one (11)</td>
<td>0.39</td>
<td>6.25</td>
<td>0.39</td>
<td>0.39</td>
<td>0.195</td>
<td>0.195</td>
</tr>
<tr>
<td>4-Epoxygeranyloxy-quinol-2-one (12)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Compound Description</td>
<td>MIC (μg/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-Geranyloxy-quinol-2-one (13)</td>
<td>250 250 1000 &gt;1000 &gt;1000 &gt;1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3-(2'-Hydroxy-3'-methylbut-3'-enyl)-4-methoxy-1-methyl-quinol-2-one (14)</td>
<td>&gt;1000 &gt;1000 &gt;1000 &gt;1000 &gt;1000 &gt;1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-Keto-3,3-di-(3'-methylbut-2-enyl)-quinol-2-one (15)</td>
<td>&gt;1000 &gt;1000 &gt;1000 &gt;1000 &gt;1000 &gt;1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-Acetyloxy-3-(1',1'-dimethylallyl)-1-methyl-quinol-2-one (16)</td>
<td>&gt;1000 &gt;1000 &gt;1000 &gt;1000 &gt;1000 &gt;1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxacillin</td>
<td>&gt;21.6 0.17 &gt;21.6 21.6 &gt;21.6 &gt;21.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vancomycin</td>
<td>0.79 0.4 &gt;25 &gt;25 &gt;25 &gt;25</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>&gt;25 0.79 0.4 &gt;25 1.57 1.57</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MRSA, meticillin-resistant *Staphylococcus aureus*.

* [NS] indicates isolated from natural sources.
Table 2

Minimum inhibitory concentrations (µg/mL) of 3-C-dimethylallylquinol-2-ones

<table>
<thead>
<tr>
<th>3-C-dimethylallylquinol-2-one</th>
<th>MRSA</th>
<th>S. aureus</th>
<th>Micrococcus luteus</th>
<th>Bacillus subtilis</th>
<th>Escherichia coli</th>
<th>Salmonella Typhimurium</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-Hydroxy-3-(3’-methylbut-2-etyl)-quinol-2-one (17)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4-Hydroxy-6-methoxy-3-(3’-methylbut-2-etyl)-quinol-2-one (18)</td>
<td>1000</td>
<td>500</td>
<td>1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4,6-Dimethoxy-3-(3’-methylbut-2-etyl)-quinol-2-one (19)</td>
<td>1000</td>
<td>&gt;1000</td>
<td>1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4-Hydroxy-6-methoxy-3-(3’-methylbut-2-etyl)-1-methyl-quinol-2-one (20)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4-Hydroxy-6,8-dimethoxy-3-(3’-methylbut-2-enyl)-1-methyl-quinol-2-one (21)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4-Hydroxy-8-methoxy-3-(3’-methyl-2’-hydroxybutyl)-1-methyl-quinol-2-one (22)</td>
<td>500</td>
<td>250</td>
<td>250</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4-Hydroxy-8-methoxy-3-(3’-methylbut-2’-enyl)-1-methyl-quinol-2-one (23)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td></td>
<td>1000</td>
<td>1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------</td>
<td>------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>Lunacridine (24) [NS]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4,6-Dimethoxy-3-(3’-methyl-2’-oxobutyl)-1-methyl-quinol-2-one (25)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4-Hydroxy-7,8-methyleneedioxy-3-(3’-methylbut-2-enyl)-quinol-2-one (26)</td>
<td>1000</td>
<td>500</td>
<td>333</td>
<td>1000</td>
<td>1000</td>
<td>&gt;1000</td>
</tr>
</tbody>
</table>

MRSA, meticillin-resistant *Staphylococcus aureus*.

*a [NS] indicates isolated from natural sources.*
Table 3

Minimum inhibitory concentrations (µg/mL) of flindersine derivatives, quinoline dimers and dihydrofuroquinolines

<table>
<thead>
<tr>
<th></th>
<th>MRSA</th>
<th>S. aureus</th>
<th>Micrococcus luteus</th>
<th>Bacillus subtilis</th>
<th>Escherichia coli</th>
<th>Salmonella Typhimurium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flindersine compound</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flindersine (27)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>7,8-Dimethoxyflindersine (28)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Veprisine (29) [NS] a</td>
<td>&gt;1000</td>
<td>125</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>N-Methylflindersine (30)</td>
<td>125</td>
<td>125</td>
<td>125</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>7-Hydroxyflindersine (31)</td>
<td>125</td>
<td>125</td>
<td>125</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>7-Hydroxy-N-methylflindersine (32)</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>7-Tetrahydropyranoxyflindersine (33)</td>
<td>250</td>
<td>125</td>
<td>250</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>7-Dimethylallyoxy-N-methylflindersine (34)</td>
<td>1000</td>
<td>500</td>
<td>250</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Quinoline dimers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quinolone dimer (35)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Ketoquinoline dimer (36)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Vepridimerine A (37) [NS] a</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Dihydrofuroquinolines</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compound</td>
<td>MIC (µg/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-Chloro-6-methoxydihydrofuro-(3,2-c)-quinoline (38)</td>
<td>&gt;1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platydesmine (39) [NS]</td>
<td>&gt;1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-Hydroxyisopropyl-6-methoxy-5-methylidihydro-furo-(3,2-c)-quinol-4-one (40)</td>
<td>&gt;1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balfouridine (41) [NS]</td>
<td>&gt;1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lemobiline (42) [NS]</td>
<td>&gt;1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MRSA, meticillin-resistant *Staphylococcus aureus*.

a [NS] indicates isolated from natural sources.
Table 4

Minimum inhibitory concentrations (µg/mL) of linear and angular furoquinolines and other quinoline compounds

<table>
<thead>
<tr>
<th></th>
<th>MRSA</th>
<th>S. aureus</th>
<th>Micrococcus luteus</th>
<th>Bacillus subtilis</th>
<th>Escherichia coli</th>
<th>Salmonella Typhimurium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linear or angular furoquinoline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-Methylfuro-(3,2-c)-quinol-4-one (43)</td>
<td>333</td>
<td>250</td>
<td>125</td>
<td>500</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>Dictamnine (44) [NS] a</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>γ-Fagarine (45) [NS] a</td>
<td>500</td>
<td>500</td>
<td>500</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Skimmianine (46) [NS] a</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4-Methoxy-2-isopropyl-furoquinoline (47)</td>
<td>500</td>
<td>500</td>
<td>1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Dehydroplatydesmine (48)</td>
<td>&gt;1000</td>
<td>500</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Evoxine (49) [NS] a</td>
<td>&gt;1000</td>
<td>1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Choisyine (50) [NS] a</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>4-Chloro-6,7-methylenedioxy-furoquinoline (51)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>6,7-Methylenedioxyfuro-(2,3-b)-quinol-4-one (52)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Other quinolines</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compound</td>
<td>MRSA</td>
<td>MRSA</td>
<td>MRSA</td>
<td>MRSA</td>
<td>MRSA</td>
<td>MRSA</td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td>---------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>2,4-Quinolinediol (53)</td>
<td>&gt;1000</td>
<td>100</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>2,4-Dichloroquinoline (54)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>2,4-Dimethoxyquinoline (55)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>2,4,8-Trimethoxyquinoline (56)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Orixine (57)</td>
<td>250</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>1000</td>
</tr>
<tr>
<td>5-Methoxy-2,2-dimethylidihydropyrano-(2,3-b)-quinoline (58)</td>
<td>500</td>
<td>333</td>
<td>500</td>
<td>1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>3,5-Diacetoxyl-2,2-dimethylidihydropyrano-(2,3-b)-quinoline (59)</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Ribalinine (60) [NS]</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
</tbody>
</table>

MRSA, meticillin-resistant *Staphylococcus aureus*.

[a] [NS] indicates isolated from natural sources.
Table 5

Minimum inhibitory concentrations (µg/mL) of selected quinolines against different strains of meticillin-resistant *Staphylococcus aureus* (MRSA)

<table>
<thead>
<tr>
<th>Compound</th>
<th>EMRSA-15</th>
<th>EMRSA-16</th>
<th>IMRSA-1</th>
<th>IMRSA-2</th>
<th>DMRSA</th>
<th>NTMRSA</th>
<th>CWMRSA</th>
<th>HMRSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,7,8-Trimethoxy-3-iodo-quinol-2-one (10)</td>
<td>125</td>
<td>62.5</td>
<td>125</td>
<td>125</td>
<td>250</td>
<td>125</td>
<td>125</td>
<td>125</td>
</tr>
<tr>
<td>4-Hydroxy-3-iodo-quinol-2-one (11)</td>
<td>0.39</td>
<td>25</td>
<td>0.097</td>
<td>0.39</td>
<td>0.049</td>
<td>0.049</td>
<td>1.56</td>
<td>1.56</td>
</tr>
<tr>
<td>Veprisine (29)</td>
<td>250</td>
<td>125</td>
<td>333</td>
<td>250</td>
<td>333</td>
<td>166.5</td>
<td>125</td>
<td>500</td>
</tr>
<tr>
<td>N-Methylflindersine (30)</td>
<td>125</td>
<td>125</td>
<td>125</td>
<td>125</td>
<td>125</td>
<td>125</td>
<td>125</td>
<td>125</td>
</tr>
<tr>
<td>7-Hydroxyflindersine (31)</td>
<td>166.5</td>
<td>166.5</td>
<td>125</td>
<td>250</td>
<td>125</td>
<td>250</td>
<td>125</td>
<td>166.5</td>
</tr>
<tr>
<td>7-Tetrahydro-pyranyloxyflindersine (33)</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>166.5</td>
<td>250</td>
<td>166.5</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>0.78</td>
<td>0.78</td>
<td>1.56</td>
<td>0.78</td>
<td>1.56</td>
<td>0.78</td>
<td>1.56</td>
<td>1.56</td>
</tr>
</tbody>
</table>

EMRSA-15, epidemic MRSA-15; EMRSA-16, epidemic MRSA-16; IMRSA-1, Irish hospital MRSA-1; IMRSA-2; Irish hospital MRSA-2; DMRSA, distinct MRSA strain; NTMRSA, non-typeable MRSA strain; CWMRSA, community-acquired Charles–Worth MRSA; HMRSA, community-acquired Hodgkin MRSA.
<table>
<thead>
<tr>
<th>Quinol-2-one</th>
<th>R1</th>
<th>R2</th>
<th>R3</th>
<th>R4</th>
<th>R5</th>
<th>R6</th>
<th>R7</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1)</td>
<td>CH₃</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>H</td>
</tr>
<tr>
<td>(2)</td>
<td>CH₃</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>H</td>
</tr>
<tr>
<td>(3)</td>
<td>CH₃</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>CH₃</td>
</tr>
<tr>
<td>(4)</td>
<td>CH₃</td>
<td>OCH₃</td>
<td>OCH₃</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>CH₃</td>
</tr>
<tr>
<td>(5)</td>
<td>H</td>
<td>OCH₃</td>
<td>OCH₃</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>H</td>
</tr>
<tr>
<td>(6)</td>
<td>H</td>
<td>OCH₃</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>H</td>
</tr>
<tr>
<td>(7)</td>
<td>H</td>
<td>OCH₃</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OCH₃</td>
<td>H</td>
</tr>
<tr>
<td>(8)</td>
<td>H</td>
<td>OCH₃</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OC₂H₅</td>
<td>H</td>
</tr>
<tr>
<td>(9)</td>
<td>H</td>
<td>OCH₃</td>
<td>OCH₃</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>I</td>
</tr>
<tr>
<td>(10)</td>
<td>H</td>
<td>OCH₃</td>
<td>OCH₃</td>
<td>H</td>
<td>H</td>
<td>OCH₃</td>
<td>I</td>
</tr>
<tr>
<td>(11)</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>I</td>
</tr>
<tr>
<td>(12)</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>Epoxidegeranyloxy</td>
<td>H</td>
</tr>
<tr>
<td>(13)</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>Geranyloxy</td>
<td>H</td>
</tr>
<tr>
<td>(14)</td>
<td>CH₃</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OCH₃</td>
<td>2'-hydroxy-3'-methylbutyl-3'-enyl</td>
</tr>
<tr>
<td>(15)</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>Keto</td>
<td>di-3'-methylbut-2'-enyl</td>
</tr>
<tr>
<td>(16)</td>
<td>CH₃</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OCOCH₃</td>
<td>1',1'-dimethylallyl</td>
</tr>
<tr>
<td>3-C-dimethylallylquinol-2-ones</td>
<td>R₁</td>
<td>R₂</td>
<td>R₃</td>
<td>R₄</td>
<td>R₅</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>-----</td>
<td>-----</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(17)</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(18)</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OCH₃</td>
<td>OH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(19)</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OCH₃</td>
<td>OCH₃</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(20)</td>
<td>CH₃</td>
<td>H</td>
<td>H</td>
<td>OCH₃</td>
<td>OH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(21)</td>
<td>CH₃</td>
<td>OCH₃</td>
<td>H</td>
<td>OCH₃</td>
<td>OH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(23)</td>
<td>CH₃</td>
<td>OCH₃</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(22) R₁=OH, (24) R₁=OCH₃

(25)

(26)
<table>
<thead>
<tr>
<th>Flindersine compound</th>
<th>R₁</th>
<th>R₂</th>
<th>R₃</th>
</tr>
</thead>
<tbody>
<tr>
<td>(27)</td>
<td>H</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>(28)</td>
<td>H</td>
<td>OCH₃</td>
<td>OCH₃</td>
</tr>
<tr>
<td>(29)</td>
<td>CH₃</td>
<td>OCH₃</td>
<td>OCH₃</td>
</tr>
<tr>
<td>(30)</td>
<td>CH₃</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>(31)</td>
<td>H</td>
<td>OH</td>
<td>H</td>
</tr>
<tr>
<td>(32)</td>
<td>CH₃</td>
<td>OH</td>
<td>H</td>
</tr>
<tr>
<td>(33)</td>
<td>H</td>
<td>Tetrahydropyranloxy</td>
<td>H</td>
</tr>
<tr>
<td>(34)</td>
<td>CH₃</td>
<td>Dimethylallyloxy</td>
<td>H</td>
</tr>
</tbody>
</table>
\[ \text{(35)} \]

\[ \text{(36)} \]

\[ \text{(37)} \]
### Dihydrofuroquinoline Compound

<table>
<thead>
<tr>
<th>Compound</th>
<th>R₁</th>
<th>R₂</th>
<th>R₃</th>
<th>R₄</th>
</tr>
</thead>
<tbody>
<tr>
<td>(41)</td>
<td>C(OH)(CH₃)₂</td>
<td>H</td>
<td>H</td>
<td>OCH₃</td>
</tr>
<tr>
<td>(42)</td>
<td>CH₃</td>
<td>CH₃</td>
<td>CH₃</td>
<td>H</td>
</tr>
</tbody>
</table>

![Compound (38)](image1)

![Compound (39)](image2)

![Compound (40)](image3)
**Linear and augular Furoquinolines**

<table>
<thead>
<tr>
<th></th>
<th>R₁</th>
<th>R₂</th>
<th>R₃</th>
<th>R₄</th>
<th>R₅</th>
</tr>
</thead>
<tbody>
<tr>
<td>(44)</td>
<td>OCH₃</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>(45)</td>
<td>OCH₃</td>
<td>H</td>
<td>H</td>
<td>OCH₃</td>
<td>H</td>
</tr>
<tr>
<td>(46)</td>
<td>OCH₃</td>
<td>H</td>
<td>OCH₃</td>
<td>OCH₃</td>
<td>H</td>
</tr>
<tr>
<td>(47)</td>
<td>OCH₃</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>C(CH₃)CH₃</td>
</tr>
<tr>
<td>(48)</td>
<td>OCH₃</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>C(CH₃)(OH)CH₃</td>
</tr>
<tr>
<td>(49)</td>
<td>OCH₃</td>
<td>H</td>
<td>OCH₂CH(OH)C(OH)(CH₃)₂</td>
<td>OCH₃</td>
<td>H</td>
</tr>
<tr>
<td>(51)</td>
<td>Cl</td>
<td>*</td>
<td>R₂-R₃ = OCH₂O</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>(52)</td>
<td>Oxo</td>
<td>*</td>
<td>R₂-R₃ = OCH₂O</td>
<td>H</td>
<td>H</td>
</tr>
</tbody>
</table>

* Methyleneedioxy ring between position R₂ and R₃ for compounds (51) and (52).
Quinolines | $R_1$ | $R_2$ | $R_3$ | $R_4$ | $R_5$
---|---|---|---|---|---
(53) | OH | H | OH | H | H
(54) | Cl | H | Cl | H | H
(55) | OCH$_3$ | H | OCH$_3$ | H | H
(56) | OCH$_3$ | H | OCH$_3$ | H | OCH$_3$

Quinolines | $R_1$ | $R_2$
---|---|---
(58) | H | OCH$_3$
(59) | OCOCH$_3$ | OCOCH$_3$